Merck and Ridgeback Initiate P-III MOVe-AHEAD Study of Molnupiravir for the Prevention of COVID-19 Infection
Shots:
- The company initiates a P-III MOVe-AHEAD trial to evaluate molnupiravir (800 mg- q12h for 5 days) vs PBO in ~1-332 participants aged 18yrs. who reside in the same household as someone with laboratory-confirmed SARS-CoV-2 infection with symptoms. The trial is being conducted globally
- The 1EPs of trial i.e.- proportion of participants with COVID-19 (laboratory-confirmed) @14days- percentage of participants with an AEs & who discontinued the study due to AEs
- The safety & efficacy of molnupiravir is also being evaluated in Part 2 of an ongoing P-III MOVe-OUT trial for non-hospitalized patients with at least one risk factor due to poor disease outcomes. The results are expected in H2’21
Ref: Businesswire | Image: Merck
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com